Table 4

Anti-CCP titer decrease in adalimumab treated patients: correlation with the clinical response to treatment
ACR response, week 24
 Week 0
 Week 24
 P
 ACR response, week 48
 Week 0
 Week 48
 P
<20% (n = 6)
 118.4 ± 34.9
 111.8 ± 48.8
 n.s.
 <20% (n = 3)
 107 ± 14.1
 68.4 ± 23.3
 n.d.
ACR 20 (n = 21)
 111.5 ± 45.9
 104.3 ± 48.5
 n.s.
 ACR 20 (n = 21)
 121.8 ± 48.2
 88.6 ± 52.6
 0.001
ACR 50 (n = 16)
 121.9 ± 45.1
 93.9 ± 46.4
 0.001
 ACR 50 (n = 13)
 119.6 ± 45.8
 73.5 ± 36.2
 0.001
ACR 70 (n = 3)
 126.8 ± 51.9
 85.9 ± 43.5
 n.d.
 ACR 70 (n = 9)
 105.3 ± 37.7
 65.3 ± 35.5
 0.003

46 anti-CCP-positive patients at baseline were included in the evaluation. Results are means ± SD. CCP, cyclic citrullinated peptide; n.d., not done; n.s., not significant.

Atzeni et al. Arthritis Research & Therapy 2006 8:R3   doi:10.1186/ar1851

Open Data